Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received an average recommendation of “Reduce” from the eight analysts that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $23.00.

Several brokerages recently issued reports on IART. Morgan Stanley began coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective for the company. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th.

Integra LifeSciences Stock Down 2.8 %

Shares of NASDAQ IART opened at $22.67 on Thursday. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The stock has a market cap of $1.75 billion, a PE ratio of -251.86, a P/E/G ratio of 0.81 and a beta of 1.17. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a 50-day moving average of $23.81 and a 200 day moving average of $21.82.

Insider Buying and Selling

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.10% of the company’s stock.

Institutional Trading of Integra LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY grew its position in Integra LifeSciences by 170.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock valued at $32,457,000 after acquiring an additional 901,600 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Integra LifeSciences by 16.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company’s stock valued at $4,505,000 after purchasing an additional 28,457 shares during the period. Woodline Partners LP purchased a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $2,512,000. Soleus Capital Management L.P. acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $28,940,000. Finally, Two Sigma Advisers LP increased its stake in Integra LifeSciences by 4.5% during the 4th quarter. Two Sigma Advisers LP now owns 536,000 shares of the life sciences company’s stock worth $12,156,000 after buying an additional 23,300 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.